Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Glaukos Corporation

< Previous 1 2 3 Next >
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the Stephens Annual Investment Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces Third Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces Second Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology Symposium
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces First Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces the Release of its 2021 Sustainability Report
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Executive Leadership Changes
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Corporation to Release Fourth Quarter and Full Year 2021 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces FDA 510(k) Clearance of iPRIME™
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
Tickers GKOS
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
From Glaukos Corporation
Via Business Wire
Tickers GKOS
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.